Living with primary liver cancer is a heavy burden for patients and their families. When doctors treat this condition, they often use a procedure called transarterial chemoembolization, or TACE. This treatment works by cutting off blood flow to a tumor while delivering chemotherapy directly to the site. While TACE is a common standard, many patients are looking for ways to improve the effectiveness of their treatment and manage their condition more successfully.
To see if adding certain herbal products could help, researchers performed a network meta-analysis. This is a complex type of study that compares multiple different treatments at once by looking at data from many different trials. They looked at data from over 2,600 patients to see what happened when three specific herbal products—Compound Banmao Capsule, Huaier Granule, and Jinlong Capsule—were used alongside the standard TACE procedure.
The results showed that adding these capsules to the standard treatment could improve the objective response rate. This is a measure of how much a tumor shrinks or disappears. Specifically, the Compound Banmao Capsule showed the highest potential for shrinking tumors compared to TACE alone. The other two options, Huaier Granule and Jinlong Capsule, also showed better results for shrinking tumors than TACE alone, though the Compound Banmao Capsule ranked the highest among the three.
When looking at the disease control rate, which measures how well the cancer is kept in check over time, the results were less clear. While the rankings showed a slight preference for the Compound Banrao and Jinlong options, the data did not reach a level of statistical significance for these specific outcomes. This means the researchers could not say for certain that these products were definitely better than TACE alone for keeping the disease under control.
It is important to keep these findings in perspective. This was a meta-analysis, which means it is a summary of other studies rather than a new clinical trial. Because the data on disease control was not statistically significant, we cannot say these products are a guaranteed success for every patient. Additionally, the study did not provide specific information on side effects or how well patients tolerated these additions.
For patients today, this research suggests that these herbal additions might offer a promising path for improving tumor shrinkage. However, because the evidence is still being gathered and the results for long-term disease control are not definitive, patients should talk to their oncology team. They can discuss how these specific options might fit into an individual treatment plan.
